Thalidomide arene oxide | 1488-25-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: Thalidomide arene oxide
• 英文别名: 4-(2,6-dioxopiperidin-3-yl)-1a,6a-dihydrooxireno[2,3-f]isoindole-3,5-dione
• CAS: 1488-25-1
• 化学式: C₁₃H₁₀N₂O₅
• 分子量: 274.23
• InChiKey: MNALUCRLHVMELD-UHFFFAOYSA-N

物化性质

• 沸点：
  135.59°C (rough estimate)
• 密度：
  0.9786 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  96.1
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2932999099

文献信息

• Compositions for inhibition of anglogenesis
  申请人：The Children's Medical Center Corporation

  公开号：EP1920773A1

  公开（公告）日：2008-05-14

  The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, anti-inflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.

  本发明包括一组能有效抑制血管生成的化合物。更具体地说，沙利度胺和各种相关化合物，如沙利度胺前体、类似物、代谢物和水解产物，已被证明可抑制血管生成和治疗血管生成导致的疾病状态。此外，抗炎药物，如类固醇和非甾体抗炎药物，可单独或与沙利度胺及相关化合物联合使用，抑制血管生成相关疾病。重要的是，这些化合物可以口服给药。
• Thalidomide and dexamethasone for the treatment of tumors
  申请人：The Children's Medical Center Corporation

  公开号：EP1920773B1

  公开（公告）日：2011-01-05
• Methods and Compositions for inhibition of angiogenesis
  申请人：D'Amato J. Robert

  公开号：US20070049566A1

  公开（公告）日：2007-03-01

  The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, antiinflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.
• US7435745B2
  申请人：——

  公开号：US7435745B2

  公开（公告）日：2008-10-14
• US7524865B2
  申请人：——

  公开号：US7524865B2

  公开（公告）日：2009-04-28